Cognitive dysfunction in Huntington¿s disease: Humans, mouse models and molecular mechanisms

dc.contributor.authorGiralt Torroella, Albert
dc.contributor.authorSaavedra, Ana
dc.contributor.authorAlberch i Vié, Jordi, 1959-
dc.contributor.authorPérez Navarro, Esther
dc.date.accessioned2022-02-17T19:17:59Z
dc.date.available2022-02-17T19:17:59Z
dc.date.issued2012
dc.date.updated2022-02-17T19:17:59Z
dc.description.abstractHuntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder due to an expanded CAG/polyglutamine repeat in the coding region of the huntingtin (htt) gene that causes the preferential degeneration of striatal neurons. Although HD is classically considered a motor disorder, cognitive decline manifests even before the appearance of motor symptoms, and reflects the impairment of additional neuronal populations, such as cortical and hippocampal neurons, in the presence of mutant htt (mhtt). Studies on cognitive dysfunction in HD patients have focused on the cortico-striatal pathway. Here we will describe that HD patients and mouse models share many cognitive defects. Alterations in hippocampal synaptic plasticity and function found in HD mouse models highlight that changes in the functioning of the hippocampal formation contribute to cognitive dysfunction in humans. The similarity between the cognitive dysfunction in HD patients and mouse models has helped to understand better how cognitive dysfunction takes place. Moreover, it validates the use of HD mice to study the molecular mechanisms involved in HD cognitive decline. Several studies in HD mouse models indicate that altered synaptic composition/function, deficient neurotrophic support, kinase/phosphatase imbalance, and transcription dysregulation play an important role in cognitive impairment. This knowledge opens the possibility of identifying relevant therapeutic targets to fight cognitive decline in HD. The finding that in HD many mechanisms are similarly altered in hippocampal and striatal neurons suggests the possibility of a common therapeutic strategy to ameliorate both cognitive and motor dysfunction.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec624227
dc.identifier.issn1879-6397
dc.identifier.urihttps://hdl.handle.net/2445/183269
dc.language.isoeng
dc.publisherIOS Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3233/JHD-120023
dc.relation.ispartofJournal of Huntington's disease, 2012, vol. 1, p. 155-173
dc.relation.urihttps://doi.org/10.3233/JHD-120023
dc.rights(c) Giralt Torroella, Albert et al., 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationCorea de Huntington
dc.subject.classificationModels animals en la investigació
dc.subject.otherHuntington's chorea
dc.subject.otherAnimal models in research
dc.titleCognitive dysfunction in Huntington¿s disease: Humans, mouse models and molecular mechanisms
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
624227.pdf
Mida:
230.52 KB
Format:
Adobe Portable Document Format